Navigation Links
According to Surveyed Oncologists in the EU5, Zytiga Has Heavily Penetrated Second-Line Treatment of Metastatic Castrate-Resistant Prostate Cancer (mCRPC) and is Displacing Jevtana to Later-Line mCRPC
Date:3/18/2013

BURLINGTON, Mass., March 18, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, despite its recent market entry, Johnson & Johnson/Janssen Biotech/Janssen Cilag's Zytiga has heavily penetrated surveyed EU5 (France, Germany, Italy, Spain and the United Kingdom) oncologists' second-line treatment of metastatic castrate-resistant prostate cancer (mCRPC) patients who have received prior treatment with docetaxel. Uptake of Zytiga is especially high in France and the United Kingdom, where, on average, approximately half of respondents' second-line patients are prescribed Zytiga.

(Logo:  http://photos.prnewswire.com/prnh/20130103/MM36784LOGO )

Among respondents in most countries, Sanofi's Jevtana is more commonly used in the third-line than the second-line setting, suggesting that second-to-market Zytiga is displacing Jevtana to later-line mCRPC. In support of this finding, most of those surveyed in all countries indicate that the recent launch of Zytiga will influence a shift in prescribing of Jevtana toward later-line mCRPC treatment in the next 12 months.

The new European Physician & Payer Forum report entitled The Dynamic Prostate Cancer Landscape: How Will European Payer and Prescriber Attitudes Shape This Competitive Market? finds that more than one-third of respondents in Germany and Spain believe Zytiga's launch will significantly influence a shift in Jevtana's prescribing, while almost one-quarter of those in Italy agree. Zytiga's more favorable side-effect profile, convenient oral administration, and mechanism of action likely explain why such a substantial percentage of physicians expect this trend. At the end of 2015, despite the anticipated approval of three new therapies—Medivation/Astellas Pharma's Xtandi, Algeta/Bayer HealthCare's radium-223, and Takeda/Millennium's orteronel—Zytiga will maintain its position as the favored second-line mCRPC therapy among surveyed EU5 physicians.

This report also finds that, in addition to robust efficacy, therapeutic innovation and demonstrable downstream cost savings are key market access levers that will encourage EU5 payers to think beyond an emerging agent's proposed price tag. Pharmaceutical innovation is key to reimbursement decision making in Italy and Spain, and, in the former, inclusion on AIFA's innovative drugs list ensures funding across regions.

"Savings in hospitalization and supportive care costs, as well as the societal benefits of improving quality of life, will help encourage uptake within countries following admission to reimbursement," said Decision Resources Senior Director Rachel Webster , Ph.D. "Costs associated with management of Jevtana's side effects may well have contributed to NICE's decision on its lack of cost-effectiveness. Furthermore, the United Kingdom's value-based pricing system, set to be implemented at the end of this year, will pave the way for consideration of wider societal benefits and associated cost savings, and the principles of this concept are increasingly evident across the EU5."

About Decision Resources
Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources Group company.

About Decision Resources Group
Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at www.DecisionResourcesGroup.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.


'/>"/>
SOURCE Decision Resources
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Handwritten Scripts Still Outpace E-Prescribing by More than 60 Percent, According to New Data
2. Food Recalls Hit Two-Year High in Fourth Quarter of 2012, According to Latest ExpertRECALL Index
3. Life Sciences Venture Capital Funding Drops 14% During 2012, According To The MoneyTree Report
4. Affluence, an Aging Population, and Anticipated Rx-to-OTC Switches Boost a Healthy $32 Billion OTC Market in China, According to Kline
5. Food Recalls Rise to Four a Day in Third Quarter, Reaching Highest Level of Activity in Eight Quarters, According to the ExpertRECALL Index
6. According to New Survey, Most Men are Not Proactive about Their Health Despite the Desire to Live Long Lives
7. European Market for Dental Instruments Surpasses $652 Million, According to New Market Research
8. Epigenomics Presents Significant Opportunities for Investment and Product Development, According to New Biotech Market Research
9. Over 123 Million Medical Device Units Recalled in Second Quarter of 2012, Reaching an Eight-Quarter High, According to the ExpertRECALL Index
10. Latest Drug Sales Data: Loss of Patent Protection Has Significant Effect, According to Drugs.com
11. Vaginal Mesh Lawsuits Pick Up Momentum, According To Pulaski & Middleman, LLC
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/4/2016)... LONDON , Feb. 4, 2016 ... Summary Global Markets Direct,s, ,Wegener Polyangiitis - ... the Wegener Polyangiitis,s therapeutic pipeline. This report ... Wegener Polyangiitis, complete with comparative analysis at various ... action (MoA), route of administration (RoA) and molecule ...
(Date:2/4/2016)... Feb. 4, 2016 Summary Breast cancer, ... and the most common cancer in women worldwide, accounting ... exceedingly prevalent. The number of women diagnosed with breast ... the number of deaths has declined due to earlier ... has been revolutionized in the past four decades, especially ...
(Date:2/4/2016)... Frontier Pharma: Chronic Obstructive Pulmonary Disease ... Chronic Obstructive Pulmonary Disease (COPD) is ... the airways and lungs. Persistent breathing difficulties and ... one of the leading causes of morbidity and ... COPD is linked to cumulative exposure to risk ...
Breaking Medicine Technology:
(Date:2/6/2016)... ... 06, 2016 , ... Research has shown that building shame ... frequency and level of relapse. , At the 2016 iaedp Symposium, ... explore the critical tasks of the recovery phase and beyond including relapse prevention ...
(Date:2/5/2016)... ... February 05, 2016 , ... Today, the Whole-Food Warrior ... that the much-anticipated feature with author Jahnavi Foster, specialist in healthy vegetarian cuisine, will ... , Each week, on his weekly Whole-Food Warrior TV show, Frank Davis highlights Whole-Food ...
(Date:2/5/2016)... Santa Rosa, CA (PRWEB) , ... February 05, ... ... are pleased to announce the addition of micro-needling services in their Napa Valley ... appearance. The founders of Plastic Surgery Associates, Dr. Canales and Dr. Furnas, are ...
(Date:2/5/2016)... ... February 05, 2016 , ... ... to funding innovative lymphoma research and serving the lymphoma community through a comprehensive ... once again host, Swirl, A Wine Tasting Event at the La Gorce Country ...
(Date:2/5/2016)... , ... February 05, 2016 , ... Regular gym users ... themselves having to wait longer to access the treadmills. It’s a predictable trend. After ... to lose weight and get in shape by joining gyms, starting new walking or ...
Breaking Medicine News(10 mins):